Scarica l'app Stockscreener
0.2146
6.70%
-0.0154
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Cyclacel Pharmaceuticals Inc Borsa (CYCC) Ultime notizie
Fitters plans to sell full stake in unit to US biotech firm - The Malaysian Reserve
Cyclacel Pharmaceuticals Shifts Focus to Cancer Drug Development - TipRanks
Cyclacel Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Cyclacel Pharmaceuticals Appoints New Directors Amid Strategic Shift - TipRanks
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results And Provides Business Update - MarketScreener
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update - The Manila Times
Cyclacel Slashes Net Loss in Half, Streamlines to Focus on Promising Cancer Drug - Stock Titan
Cyclacel Pharmaceuticals Delays 10-K Filing - TipRanks
CYCC stock touches 52-week low at $0.29 amid sharp annual decline By Investing.com - Investing.com South Africa
CYCC stock touches 52-week low at $0.29 amid sharp annual decline - Investing.com
StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Financial Contrast: Cellectar Biosciences (NASDAQ:CLRB) versus Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cyclacel Pharmaceuticals to offer convertible preferred stock in private placement - MSN
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering Of Convertible Preferred Stock - Marketscreener.com
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock - The Manila Times
Cyclacel's Latest $1M Financing Deal Reveals Extended Survival Strategy Through Q3 2025 - Stock Titan
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World
Cyclacel Pharmaceuticals’ Change of Control Transaction and Appointment of New Executive Leadership - Global Legal Chronicle
(CYCCP) Trading Advice - news.stocktradersdaily.com
Cyclacel Pharmaceuticals (CYCC) Projected to Post Earnings on Tuesday - The AM Reporter
CYCLACEL PHARMACEUTICALS Earnings Preview: Recent $CYCC Insider Trading, Hedge Fund Activity, and More - Nasdaq
StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cyclacel Pharmaceuticals acquires cancer drug assets By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals acquires cancer drug assets - Investing.com
Cyclacel stock plunges to 52-week low at $0.3 amid market challenges - Investing.com Australia
Cyclacel stock plunges to 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals (CYCC) to Release Earnings on Tuesday - Defense World
Cyclacel stock plunges to 52-week low of $0.31 amid market challenges - MSN
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com - Defense World
Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Cyclacel Pharmaceuticals interim CEO David Lazar sells $5.5 million in stock - Investing.com India
Cyclacel Pharmaceuticals Announces New Leadership and Restructuring - TipRanks
Cyclacel Pharmaceuticals Says Datuk Dr.Doris Wong Sing Ee Elected As CEO & Executive Director - Marketscreener.com
Cyclacel Pharmaceuticals Expands Executive Leadership Team - citybiz
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership - The Manila Times
Investor Network: Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Who Now Controls Cyclacel? New Investor Takes 70% Ownership in $6.3M Leadership Overhaul - StockTitan
Buffett’s on the Sidelines – Should You Follow? - The Globe and Mail
Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, on Innovative Targeted Therapies for Advanced - DocWire News
Cyclacel Pharmaceuticals amends agreement with CEO By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals amends agreement with CEO - Investing.com
(CYCCP) Trading Report - news.stocktradersdaily.com
Head-To-Head Review: Cyclacel Pharmaceuticals (NASDAQ:CYCC) vs. Silence Therapeutics (NASDAQ:SLN) - Defense World
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $25 million in funding from Helena Special Opportunities LLC - Marketscreener.com
Cyclacel Pharmaceuticals streamlines operations, plans asset purchase - MSN
2.65%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):